We are committed to upholding the same quality standards in developing and producing biosimilars as the originator biologics while supporting the unique needs of patients, practitioners and the Canadian healthcare system.
Our commitment to biosimilars come to life in our state-of-the art research and development centre based in Eysins, Switzerland which is supported by a large team of biosimilar experts from over 25 nationalities. Watch our video below to understand our continued development of reliable, high quality biosimilars for autoimmune diseases and oncology.
Our biosimilars pipeline
We are committed to providing valued biologic treatments through the development of new immunology and oncology therapies in our expanding biosimilars portfolio.
Our pipeline includes biosimilars of adalimumab (Idacio® currently commercialized in 35 countries, Aug. 2022) and tocilizumab (MSB11456 – currently in development) in the autoimmune disease (immunology) therapy area, and a biosimilar of pegfilgrastim in the oncology therapy area.
In addition, we have multiple candidates in early-phase development, in both autoimmune and oncology therapy areas.